Medicare Enrolled
Dr. Bijoy Telivala, M.D.
Hematology & Oncology · Jacksonville, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Telivala from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Telivala?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Telivala
Dr. Bijoy Telivala is a hematology & oncology specialist in Jacksonville, FL, with 17 years of NPI registration. Based on federal Medicare data, Dr. Telivala performed 66,545 Medicare services across 2,256 unique beneficiaries.
Between the years covered by Open Payments, Dr. Telivala received a total of $3,398 from 27 pharmaceutical and/or device companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Telivala is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 13% volume in FL
$3,398 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 106137 | Clear | January 31, 2028 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗66,545
Medicare services
Top 13% in FL for hematology & oncology
2,256
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,914 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
41,250 | $1 | $4 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
11,700 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
4,000 | $6 | $27 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,668 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 1,620 | $18 | $38 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
990 | $8 | $18 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
986 | $8 | $41 |
| Injection, granisetron hydrochloride, 100 mcg | 510 | $0 | $41 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
478 | $63 | $104 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
372 | $96 | $162 |
| MRI contrast dye injection (gadoterate) Administration of gadoterate meglumine, a contrast agent, in a 0.1 ml dose. |
359 | $0 | $25 |
| Anti-nausea injection (Aloxi/palonosetron) | 340 | $1 | $75 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
313 | $22 | $90 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
241 | $10 | $42 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
205 | $98 | $355 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 159 | $135 | $2,250 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
128 | $46 | $160 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
126 | $62 | $115 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
91 | $50 | $500 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
86 | $169 | $535 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
80 | $1,065 | $2,400 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
78 | $1 | $4 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 76 | $385 | $1,000 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
75 | $15 | $55 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
75 | $24 | $84 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
70 | $72 | $70 |
| Blood creatinine level test A blood test that measures the amount of creatinine, a waste product from muscle wear and tear, to help assess kidney function. |
67 | $5 | $29 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
66 | $22 | $80 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
43 | $12 | $55 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
42 | $2 | $97 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
40 | $103 | $225 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
37 | $129 | $265 |
| CT scan of chest, without contrast A computed tomography scan of the chest area that uses X-rays to create detailed images without the use of contrast dye. |
35 | $41 | $310 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
33 | $24 | $130 |
| CT scan of abdomen and pelvis, without contrast A computed tomography scan that creates detailed images of the abdominal and pelvic organs. The procedure is performed without the use of intravenous contrast dye. |
25 | $74 | $270 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
25 | $1 | $7 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
19 | $9 | $40 |
| Whole body nuclear medicine scan with CT A combined imaging procedure using nuclear medicine and CT scans to visualize the entire body. |
14 | $1,092 | $2,490 |
| Biopsy of bone marrow | 12 | $124 | $407 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
11 | $137 | $330 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
63.2% high complexity
31.7% medium
5.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,398
Total received (2018-2024)
Avg $485/year across 7 years
Bottom 45% in FL for hematology & oncology
27
Companies
54
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,629 (77.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$769 (22.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$119
2023
$66
2022
$165
2021
$136
2020
$59
2019
$2,654
2018
$198
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$2,641
Boehringer Ingelheim Pharmaceuticals, Inc.
$120
Seagen Inc.
$87
Novartis Pharmaceuticals Corporation
$70
Janssen Biotech, Inc.
$60
Seattle Genetics, Inc.
$54
GlaxoSmithKline, LLC.
$41
Merck Sharp & Dohme Corporation
$41
Incyte Corporation
$34
Octapharma USA, Inc.
$27
Daiichi Sankyo Inc.
$18
Innate Pharma, Inc
$16
Bayer HealthCare Pharmaceuticals Inc.
$16
Astellas Pharma US Inc
$15
ABBVIE INC.
$14
Bayer Healthcare Pharmaceuticals Inc.
$14
TAIHO ONCOLOGY, INC.
$14
Immunocore Limited
$13
Karyopharm Therapeutics Inc.
$12
Gilead Sciences, Inc.
$12
Global Blood Therapeutics, Inc.
$12
Eisai Inc.
$12
Lexicon Pharmaceuticals, Inc.
$11
Aurobindo Pharma USA, Inc.
$11
Genentech USA, Inc.
$11
Ipsen Biopharmaceuticals, Inc
$11
MEDIVATION FIELD SOLUTIONS LLC
$10
Top 3 companies account for 83.8% of total payments
Associated products mentioned in payments ›
ADCETRIS · Aliqopa · BOSULIF · DARZALEX · ELIQUIS · Enhertu · FEMARA · Fabhalta · Folotyn · GAZYVA · IBRANCE · INLYTA · JARDIANCE · KEYTRUDA · KIMMTRAK · LONSURF · Lenvima · Lumoxiti · MONJUVI · Nubeqa · OXBRYTA · PROMACTA · RYBREVANT · SCEMBLIX · SUTENT · TASIGNA · VENCLEXTA · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XOSPATA · XPOVIO · XTANDI · Xermelo · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (77%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $5 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
103
Per 100K population
10.2
County median income
$68,447
Nearest hospital
MAYO CLINIC
5.7 mi
5.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Telivala is a mixed practice specialist, with above-average Medicare volume (top 13% in FL), with speaking/promotional industry engagement, with 17 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Telivala experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Telivala performed 41,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Telivala receive payments from pharmaceutical companies?
Yes. Dr. Telivala received a total of $3,398 from 27 companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Telivala's costs compare to other hematology & oncology specialists in Jacksonville?
Dr. Telivala's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Telivala) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Jacksonville
Browse hematology & oncology specialists in Jacksonville ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in FL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in FL
Which FL hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology